Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a poly peptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Abstract: The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Abstract: The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: Disclosed embodiments may include a method for intelligent bookout discrepancy detection. The system may receive bookout data from an automotive dealer, which may include dealer-provided vehicle information that includes a dealer price and dealer-listed features. The system may identify a vehicle identification number from the dealer-provided vehicle information. The system may retrieve third-party vehicle information including at least one of a third-party price and third-party listed features from one or more third party sources using the vehicle identification number. The system may aggregate the third-party vehicle information from the one or more third party sources. The system may determine that a bookout discrepancy exists by comparing the dealer price to the third-party price and comparing dealer-listed features to third-party listed features. The system may flag a contract associated with the bookout data for further review.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: A device (10) to deliver fluid to an ear includes: a handle portion (12) including a proximal end and a distal end; a needle sub-assembly (26) coupled to the distal end of the handle portion (12) and including a bent needle (38); and tubing (36) coupled to the proximal end of the handle portion (12). The bent needle (38) extends through the handle portion (12) and fluidly connects directly to the tubing (36).

Abstract: A method, electromagnetic switch, controller and program product, when energizing an electromagnetic coil to urge a selected shoe into a diverting path downstream of the electromagnetic switch, reverse current flow during at least a portion of the time that the electromagnetic coil is energized to recover energy from the electromagnetic coil.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: The present disclosure discussed a handpiece for trans-canal delivery of a therapeutic substance to the inner ear. The handpiece can be inserted into the middle ear via a surgical tympanotomy approach. The handpiece can enable a controlled injection of a therapeutic substance directly through the round window membrane and into the inner ear. The direct delivery of the therapeutic substance to the inner ear can enable the delivery of a precise amount of therapeutic substance into the inner ear. Because the therapeutic substance is delivery directly to the inner ear the delivery of the therapeutic substance is not subject to limitations on molecule size and inconsistent diffusion rates that are present when therapeutic substances are diffused across the round window membrane.

Abstract: A method, electromagnetic switch, controller and program product, when energizing an electromagnetic coil to urge a selected shoe into a diverting path downstream of the electromagnetic switch, reverse current flow during at least a portion of the time that the electromagnetic coil is energized to recover energy from the electromagnetic coil.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: A method, electromagnetic switch, controller and program product utilize multiple electromagnetic coils that, whenever it is desirable to divert a shoe, are operated in sequence to urge the shoe into a diverting path downstream of the electromagnetic switch. The multiple electromagnetic coils may also be used in combination with a downstream permanent magnet such that energization of the electromagnetic coils appropriately positions the shoe adjacent the permanent magnet such that the permanent magnet can further urge the shoe towards the diverting path.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: A method and network entity for extending communication coverage in a network between a network entity and a wireless device. The method includes determining that the wireless device qualifies for coverage extension, the determining including that deriving appropriate transmission parameters for the wireless devices results in one of a lowest possible or most robust modulation and coding scheme (MCS), and determining achievable transmission performance parameters for the wireless device. If the determined achievable transmission performance parameters do not meet a set of pre-established transmission criteria, the downlink transmission power to the wireless device is increased.

Abstract: A method and network node for performing link adaption are disclosed. In one embodiment, a channel state information, CSI, measurement is received from a wireless device. An information carrying capacity, ICC, over a number of scheduling blocks, SBs, for a plurality of modulation formats for a target criteria is determined based at least in part on the CSI measurement from the wireless device. A modulation format of the plurality of modulation formats with a maximum ICC is selected. A transport block size, TBS, is determined for the selected modulation format. Link adaptation is performed based on the determined TBS.